Osteoporosis - Pathophysiology and diagnosis. Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
|
|
- Bartholomew Carter
- 6 years ago
- Views:
Transcription
1 Osteoporosis - Pathophysiology and diagnosis Bente L Langdahl Department of Endocrinology Aarhus University Hospital Aarhus, Denmark
2 Objective General knowledge about osteoporosis Optimise your protocols with respect to Selection of patients and controls Selection of donors of cells, blood or tissue samples
3 Anatomy and physiology of the skeleton Supportive organ, that ensures shape and mobility of the body Important part of the calcium homeostasis
4 Anatomy and physiology Cortical bone ca. 80 % Trabecular bone ca. 20 % Cells Osteoclasts Osteoblasts Osteocytes Lining cells Matrix Collagen Non-collagenous Minerals
5
6 Matrix Collagen (> 90 %) Non-collagenous glycoproteins osteocalcin (BGP) osteonectin glucosaminoglycans phospholipids
7 Mineral Calcium and phosphate are initially deposited as calcium-phosphate-salts Afterwards the salts are changed to hydroxyapatite C 10 (PO 4 ) 6 (OH) 2 Older bone is more mineralised than newly formed bone
8 Modeling During growth the shape of the skeleton is changed
9
10 Remodeling Replacement of old bone with new Repair of microfractures Structural adaptation to changes in the physical load pattern Every 2nd-3rd year on trabecular surfaces, but only every 10th year in cortical bone
11
12
13
14
15
16
17
18
19
20
21
22 Age- and menopause related changes in bone mass Peak bone mass (25-35 years of age) Genetic factors determine peak bone mass Nutrition, physical activity, diseases etc influence if the genetically determined peak bone mass is reached Age related bone mass (after 35 years of age) % the bone mass is lost every year Genetic, nutritional and health related factors influence the size of the yearly bone loss Menopause related bone loss (menopause) Up to 5 % yearly for 2-5 years Cessation of endogenous estrogen production
23 Pathogenesis Bone mass throughout life Growth Exchange and repair Calcium in the skeleton man women years
24 Calcium homeostasis MAGNESIUM 25 (OH) D
25 Definition of osteoporosis Osteoporosis is a disease with reduced bone mass and changes in microarchitecture The amount of bone mass and the strength of the bone tissue are reduced to an extent where fractures occur with limited trauma or no trauma at all
26 Operational definition of osteoporosis WHO: Bone mass at the spine or hip is reduced below 2.5 standard deviations of the normal bone mass in young adults of the same sex T-score i lumbar spine or hip < -2.5
27 Pathogenesis Normal bone turnover before age 35 Osteoblast insufficiency Bone turnover with loss after age 35 Osteoclasts resorb bone Osteoclasts resorb bone Osteoblasts form new bone Osteoblasts form new bone, but in insufficient amount
28
29 Risk factors for osteoporosis Genetics Lumbar spine Femoral neck Intrapair correlation coefficients rmz h = 0.92 rdz Intrapair correlation coefficients rmz h = 0.73 rdz 38 monozygotic twin pairs 27 dizygotic twin pairs Pocock et al. J Clin Invest 80, (1987)
30 Risk factors for osteoporosis Body weight Hip fractures pr women years < to to to 50 >50 Changes in body weight after 25 years of age in percentage Cummings et al. NEJM 332, , 1995
31 Risk factors for osteoporosis Tobacco consumption Relative risk for hip fracture based on observation of women and men Smokers Non-smokers Women Men Høidrup et al. Int J Epidemiol 29, 253-9, 2000
32 Risk factors for osteoporosis Alcohol consumption men women 3 population surveys in Copenhagen og 307 first hip fractures in women and men Alcohol consumption below 13 and 27 units for women and men, respectively, was not associated with increased risk of fracture RR of hip fracture with alcohol consumption (units pr. week) ( ) 5.28 ( ) 1.44 ( ) >70 Men Women S Høidrup et al. Am J Epidemiol 148, , 1999
33 Risk factors for osteoporosis Previous fracture Previous fracture New fracture RR Distal forearm Hip 1.5 Shoulder Hip 2.5 Hip Hip One vertebrae New vertebrae 5.0 Two vertebrae New vertebrae 12.0
34 Risk factors for osteoporosis Familial predisposition Low body weight (BMI<19) Previous low-energy fracture Early menopause (<45 years) Smoking Alcohol consumption above recommended level Low intake of calcium and vitamin D Immobilisation Diseases and medical treatments associated with osteoporosis: Systemic treatment with glucocorticoids: Prednisolone > 5 mg daily > 3 months Rheumatoid arthritis Anorexia nervosa Malabsorption/Gastrectomi Primary hyperparathyroidism Hyperthyroidism Organ transplantation Renal insufficiency Cushings disease Mastocytosis Osteogenesis imperfecta Multiple Myeloma Aromatase inhibitors
35 Development of osteoporosis Bone mass Bone mass Menopause MP + 10 Menopause MP + 10 Age Age
36 Potential mediators RANK, RANKL, OPG RANK Ligand is Essential for Osteoclast Formation, Function and Survival CFU-M RANKL RANK Pre-Fusion Osteoclast Growth Factors Hormones Cytokines Multinucleated Osteoclast Osteoblast Activated Osteoclast Bone Boyle et al. Nature. 2003;423:337-42
37 Potential mediators Osteoclast Activation RANK, RANKL, OPG Osteoclast Formation, Function and Survival Inhibited by OPG OPG RANKL RANK CFU-M Pre-Fusion Osteoclast Growth Factors Hormones Cytokines Multinucleated Osteoclast Osteoblast Mature Osteoclast Bone Boyle et al. Nature. 2003;423:337-42
38 Potential mediators RANK, RANKL, OPG McClung et al. NEJM :821-31
39 Potential mediators RANK, RANKL, OPG McClung et al. NEJM :821-31
40 Potential mediators Cannabonoid receptors p<0.001 CB 1 knock out mice Wild type controls 0.1 p<0.02 BMD (g/cm 2 ) CB1 KO WT FN LS Idris et al. Nat Med :774-9
41 Potential mediators Cannabonoid receptors Change in trabecular BMD Percentage p<0.001 p<0.001 ** **: p<0.002 vs OVX ** ** C57BL/6 mice OVX at 9 weeks Treatment with CBreceptor antagonist for 21 days Sham+ AM Ovx +vehicle Ovx +AM Ovx +AM Ovx +AM Idris et al. Nat Med :774-9
42 Potential mediators Sclerostin Sclerosteosis in an uncommon, autosomal recessive, progressive, sclerosing bone dysplasia characterised by generalised osteosclerosis and hyperostosis of the skeleton Affecting mainly skull and mandible Facial paralysis and hearing loss Gigantism and hand abnormalities Skeletal deformities do not occur at birth Van Buchem disease similar but without the gigantism and hand abnormalities Caused by mutations in the SOST gene, leading to reduce production of sclerostin
43 Potential mediators Sclerostin
44 Potential mediators Sclerostin hmsc Winkler et al. EMBO J 2003
45 Potential mediators Sclerostin SOST transgenic mice Winkler et al. EMBO J 2003
46 Sclerostin: Wnt antagonist Baron & Rawadi et al. Endocr :
47 Sclerostin: Wnt antagonist 3-5 years old female monkeys treated with sclerostin antibodies. P1NP and osteocalcin increased Bone formation increased (histomorphometry) BMD and bone strength increased (Ominsky et al. ASBMR 2006) 18 months old female rats, OVX at 6 months of age Increased cortical area (microct) and strength Increased trabecular BV and thickness (Ominsky et al. ASBMR 2007) 11 months old female rats, OVX at 6 months of age 5 weeks: Scl-Ab 1-25 mg/kg twice a week BV/TV: % Increased osteoblast surface, unchanged osteoclast surface (Li et al. ASBMR 2007) 16 months old male rats 5 weeks: Scl-Ab 5-25 mg/kg twice a week BMD: % Increased s-osteocalcin, but not s-ctx (Li et al. ASBMR 2007)
48 Development of osteoporosis Sambrook and Cooper Lancet 367: , 2006
49 Development of osteoporosis Sambrook and Cooper Lancet 367: , 2006
50 Diagnosis Patient history X-ray fractures DXA bone mass Biochemistry secondary causes
51 X-ray Can not measure bone mass Identification af vertebral fractures Valuable in investigation of patients with back pain 20 % reduction of the height of the vertebrae Patients with low-energy fractures of the spine has a clinical significant sign of osteoporosis and should be investigated further and treated
52 Cholesterol and the risk of heart disease Cholesterol and heart disease 12 Relative risk st quart. 2nd quart. 3rd quart. 4th quart. WHO rapport 1994
53 Bone mass (BMD) and the risk of fracture Bone mass and fracture Relative risk st quart. 2nd quart. 3rd quart. 4th quart. WHO rapport 1994
54 DXA
55 WHO s definition of osteoporosis - i relation to bone mass BMD or BMC: BMD or BMC T-score: -4, x Z-score: -2,1 Age T-score: Z-score: Interpretation: Deviation (SD) from young adults of same sex Deviation (SD) from individuals of same age and sex Normal: T-score > -1 Osteopenia: T-score < -1 Osteoporosis: T-score < -2,5 Severe osteoporosis: T-score < -2,5 + low energy fracture WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva 1994
56 WHO s definition of osteoporosis - i relation to bone mass BMD or BMC Normal Osteopenia T-score = -1 T-score = -2.5 Osteoporosis Alder WHO Study Group: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva 1994
57 DXA examination of BMC and BMD Xray of the scanned area Figure, that illustrate the persons BMD i relation to the normal ranges Result presented as BMD, T- and Z-scores and in percentage of the average for young individuals (PR) and for individuals of same age and sex as the examined person (AM)
58 DXA examination of BMC and BMD Figure, that illustrate the persons BMD i relation to the normal ranges Result presented as BMD, T- and Z-scores and in percentage of the average for young individuals (PR) and for individuals of same age and sex as the examined person (AM)
59 DXA examination of BMC and BMD Xray of the scanned area Figure, that illustrate the persons BMD i relation to the normal ranges Result presented as BMD, T- and Z-scores and in percentage of the average for young individuals (PR) and for individuals of same age and sex as the examined person (AM)
60 DXA examination of BMC and BMD Figure, that illustrate the persons BMD i relation to the normal ranges Result presented as BMD, T- and Z-scores and in percentage of the average for young individuals (PR) and for individuals of same age and sex as the examined person (AM)
61 Screening for secondary osteoporosis Analysis formål Purpose b-hgb, b-leukocytes, b-platelets, SR s-potassium, s-sodium, s-phosphate s-creatinine s-calcium, s-pth og 25-hydroxy-vitamin-D s-alkaline phosphates s-transaminases s-tsh s-fsh, s-testosterone, s-estradiol Malignancy? Adrenal-/renal disease? Renal disease? Hyper- or hypoparathyroidism Increased bone turnover / liver disase? Liver disease? Thyroid disease? Hypogonadal? / menopause? Hypogonadisme hos mænd?
62 Who should receive medical treatment? Patients with low-energy fracture of the spine or hip - independent of age Individuals with one or more risk factors for osteoporosis and a BMD T-score < women after menopause - men after years Patients who are being treated with prednisolone (>5 mg for 3 months) and have a BMD T-score < -1 - independent of age
63 Risk of hip fracture Hip fractures (1000 women year) > 5 BMD lowest 1/3 middle 1/3 highest 1/3 0 to 2 3 to 4 Number of risk factors Cummings et al. NEJM 332, , 1995
64 FRAX
65 FRAX
66 Treatment Bone friendly lifestyle Quit smoking Physical exercise Prevent falls Calcium og vitamin D Medical treatment Hip protectors Patient education
67 Calcium and vitamin D Calcium 1000 mg Vitamin D IU (20-30 ug)
68 Medical treatment of osteoporosis Estrogen and Testosterone Selective Estrogen Receptor Modulators Bisphosphonates Strontium PTH
69 Antiresorptive treatment Bone remodeling with loss after the age of 35 Bone remodeling with HRT, SERM, strontium and bisphosphonates Osteoclasts resorb bone Osteoblasts forms new bone, but in insufficient amounts Reduced remodeling frequence
70 Effect of Alendronat on new frx Fractures Percentage of patients with fractures % reduction p<0,001 placebo Alendronat 51 % reduction p<0,01 placebo Alendronat 2027 postmenopausal women years osteoporosis vertebral fractures Treatment for 3 years with Alendronat 10 mg daily placebo 500 mg calcium IU vit.d Symptomatic vertebral fractures Hip fractures Black, et al. Lancet 1996; 348:
71 Anabolic treatment Bone remodeling with loss after the age of 35 Bone remodeling with PTH Osteoclasts resorb bone Osteoclasts resorb bone Osteoblasts forms new bone, but in insufficient amounts Osteoblasts perform new bone also on resting surfaces
72 Effect of Teriparatide on fracture risk New vertebral fractures New non-vertebral fractures % red. p<0, % red. p<0, placebo PTH 20 0 placebo PTH postmenopausal women with osteoporosis (1-4 vert frx) treated with placebo, PTH 20 or 40 ug sc daily for 18 months (average) All women received 1000 mg calcium and IU vitamin D daily Neer et al. NEJM 2001: 344,
73 Treatments available PTH Bisphosphonates Incidence per 1000 women/year HRT SERM Vertebral Forearm Hip Strontium ranelate Age (years)
74 Upcomming new treatment: RANKL antibody 412 postmenopausal women with osteoporosis/osteopenia: BMD T-score <-1.8 Denusumab at different dosages and interval McClung et al. NEJM 2006;354:
75 Impact of this knowledge Choose your patients, controls, animals or cells carefully Exclude patients with secondary osteoporosis Mild hyperthyroidism or vitamin D deficiency Glucocorticoid treatment Match for confounders Physical activity Menopausal status Sex and age Keep your mind open for new observations Many pathways are probably still unrecognised
Assessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationA KL/R / AN A K/O / P O G G
Outline and New Treatments on the Horizon Steven R. Cummings, MD CPMC and UCSF San Francisco Coordinating Center Support from Lilly and Amgen New treatments, new mechanisms of action Cathepsin K inhibition
More information7/5/2016. We need drugs that. Disclosures. New Osteoporosis Treatments. What we have today. Maintain or promote bone formation
New Osteoporosis Treatments Disclosures Mary L. Bouxsein, PhD Department of Orthopedic Surgery Harvard Medical School, Boston, MA Advisory Board: Research funding: Merck, Eli Lilly, Radius Merck, Amgen
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationUpcoming Agents for Osteoporosis
Upcoming Agents for Osteoporosis May 5, 2017 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Professorial Fellow, Institute of Health and Ageing Australian Catholic
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationHRT and Risedronate Combined Anabolic and Antiresorptive Therapy
Optimizing Combined and Sequential Osteoanabolic and Antiresorptive Therapy Benjamin Leder, M.D. Endocrine Unit Massachusetts General Hospital Boston, MA Antiresorptive and Osteoanabolic Therapies Increase
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationNEW HORIZONS IN OSTEOPOROSIS THERAPY. Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN
NEW HORIZONS IN OSTEOPOROSIS THERAPY Sundeep Khosla, M.D. Mayo Clinic, Rochester, MN DISCLOSURES SUNDEEP KHOSLA, M.D. Investigator-initiated grant Merck No non-fda approved recommendations RISK ASSESSMENT
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationNew treatment targets in osteoporosis
National University of Athens Greece New treatment targets in osteoporosis Gourzi Vassiliki PhD Candidate Dept. of Pathophysiology School of Medicine Bone remodeling Physiological process < bone tissue
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOsteoporosis: current treatment and future prospects. Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus
Osteoporosis: current treatment and future prospects Juliet Compston Professor Emeritus of Bone Medicine Cambridge Biomedical Campus Disclosures Consultancy and speaking fees for Gilead, related to development
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationHot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis
Hot Topics in Bone Disease in 2017: Building Better Bones Breaking News in Osteoporosis Aromatase Inhibitor-Induced Bone Loss in Early Breast Cancer Rachel Pessah-Pollack, M.D., F.A.C.E. Mount Sinai School
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationDiagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.
Diagnosis and Treatment of Osteoporosis Department of Endocrinology and Metabolism Ajou University School of Medicine Yoon-Sok CHUNG WCIM, COEX, Seoul, 27Oct2014 Case 1 71-year old woman Back pain Emergency
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationNew treatments of osteoporosis
HOSTED BY Available online at www.sciencedirect.com ScienceDirect Osteoporosis and Sarcopenia 1 (2015) 4e21 Review article New treatments of osteoporosis http://www.elsevier.com/locate/afos Bente L. Langdahl
More informationDrugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics
Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationOSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010
OSTEONECROSI DEI MASCELLARI (ONJ): PREVENZIONE, DIAGNOSI, TRATTAMENTO UPDATE 2010 Alessandria, 5 giugno 2010 Novità nel trattamento dell osteoporosi Stefania Boldini Francesco Bertoldo Dipartimento di
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationNew Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence
New Therapeutic Directions: Osteoanabolic and Antiresorptive Therapy in Combination Therapy and in Sequence John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationOsteoporosis in Men Professor Peter R Ebeling
Osteoporosis in Men MD FRACP Head, Department of Medicine, School for Clinical Sciences Monash Health Translation Precinct Monash University, Clayton, Victoria 1 MonashHealth Potential Conflicts Departmental
More informationDISCLAIMER DO NOT DISTRIBUTE
DISCLAIMER The information contained in this presentation is not intended as a substitute for professional medical advice, diagnosis, or treatment. It is provided for educational purposes only. You assume
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationBecause the low bone mass and deterioration
OSTEOPOROSIS A look at recent expert guidelines and key studies in bone health, the findings of which affect your patients young and old Steven R. Goldstein, MD Dr. Goldstein is Professor of Obstetrics
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationAACE Southern States Chapter Lecture. Basics
AACE Southern States Chapter Lecture Unusual Bone Cases Basics Osteoporosis Osteomalacia Renal Osteodystrophy Multiple Myeloma 1 Osteoporosis Definition Modeling, Bone Remodeling Bone Resorption > Bone
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationMusculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients
Musculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients Learning Objectives Define osteoporosis and explain how it is diagnosed. Describe the main risk factors for developing osteoporosis.
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationSummary. Treatment. a larger extent than predicted. spine much faster and to. that fracture protection is greater
The Future of Ost eoporosis Care in Research and Practice ACOI Luncheon October 26, 2010 Steven T Harris MD FACP Clinical i l Profess sor of fmedicine i University of California, San Francisco Treatment
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationAssessment and management of glucocorticoid-induced osteoporosis
PRESCRIBING IN PRACTICE n Assessment and management of glucocorticoid-induced osteoporosis Gerald Tracey and Tehseen Ahmed Glucocorticoid-induced osteoporosis (GIO) is the most prevalent form of secondary
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More information10/26/2017. Aging Population = more osteoporosis
Sandra Scholten, FNP-BC Discuss burden of osteoporosis (OP) and clinical consequences of OP fractures. Define OP and techniques used to assess bone density and quality. Improve awareness, diagnosis, and
More informationNormal Bone Health and Bone Disease. Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017
Normal Bone Health and Bone Disease Mr Ryan Trickett Consultant Hand and Wrist Surgeon 6 th February 2017 Learning outcomes Understand the structure and function of bone and articular cartilage Explain
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationAlendronate sodium in the management of osteoporosis
REVIEW Alendronate sodium in the management of osteoporosis P J J Prinsloo 1 D J Hosking 2 1 Dept of Clinical Chemistry, City Hospital, Nottingham, UK; 2 Dept Endocrinology and Diabetes, City Hospital,
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationOsteoporosis, Osteomalasia & rickets. Bone disorders
Osteoporosis, Osteomalasia & rickets Bone disorders Thank You for Your comments Voice--- Ok Lecture too long--- this is in schedule??? More interaction--- I can do that inshalla Slides are crowded--- but
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationBeyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO
Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship
More informationWhat is Osteoporosis?
What is Osteoporosis? Systemic skeletal disease characterized by: low bone mass (T-score < -2.5) biochemically normal bone microarchitectural deterioration of bone tissue Hallmark- Increased bone fragility
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOsteoporosis: Current Management Strategies
Osteoporosis: Current Management Strategies Ambrish Mithal*, Nidhi Malhotra** *Senior Consultant, **Clinical Associate, Department of Endocrinology and Diabetes, Indraprastha Apollo Hospital, Sarita Vihar,
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationVasu Pai FRACS, Nat Board, MCh, M.S
Vasu Pai FRACS, Nat Board, MCh, M.S Composition of bone Mineral 70% Protein 22% Water 8% On osteoclast precurssor On Osteoblast Osteoporosis Dx No clinical lsigns No blood tests Gold standard: Bone
More informationBONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology
BONE REMODELLING Tim Arnett Department of Anatomy and Developmental Biology University College London The skeleton, out of sight and often out of mind, is a formidable mass of tissue occupying about 9%
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More information